1. Home
  2. ANL vs RMIX Comparison

ANL vs RMIX Comparison

Compare ANL & RMIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

BUY

Current Price

$10.74

Market Cap

998.8M

Sector

N/A

ML Signal

BUY

Logo Suncrete Inc. Class A Common Stock

RMIX

Suncrete Inc. Class A Common Stock

BUY

Current Price

$9.31

Market Cap

1.2B

Sector

Industrials

ML Signal

BUY

Company Overview

Basic Information
Metric
ANL
RMIX
Founded
2004
N/A
Country
Singapore
United States
Employees
N/A
N/A
Industry
Building Materials
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
998.8M
1.2B
IPO Year
2022
2026

Fundamental Metrics

Financial Performance
Metric
ANL
RMIX
Price
$10.74
$9.31
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
6
Target Price
★ $29.50
$22.50
AVG Volume (30 Days)
310.2K
★ 576.4K
Earning Date
08-14-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$243.83
$131.09
Revenue Next Year
N/A
$42.73
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$9.25
52 Week High
$17.25
$25.50

Technical Indicators

Market Signals
Indicator
ANL
RMIX
Relative Strength Index (RSI) 36.09 17.33
Support Level $8.96 N/A
Resistance Level $12.49 $18.12
Average True Range (ATR) 1.45 0.61
MACD -0.40 -0.03
Stochastic Oscillator 5.63 1.18

Price Performance

Historical Comparison
ANL
RMIX

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

About RMIX Suncrete Inc. Class A Common Stock

Suncrete Inc is a ready-mix concrete logistics and distribution platform operating across Oklahoma and Arkansas. Ready-mix concrete is a crucial building material that is used in the vast majority of infrastructure, commercial and residential construction projects. The company's ready-mix concrete business engages principally in the precise formulation, efficient production and on-time delivery of ready-mix concrete to the customers' job sites. It serves substantially all end markets of the construction industry in the select geographic markets. The company earns revenue prominently from the production and delivery of ready-mix concrete, with the majority revenue generated from orders under master purchase agreements or through direct sales to third-party contractors and suppliers.

Share on Social Networks: